Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol-Reference-Cited by-同舟云学术

Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol

Published:2006-03 Issue:3 Volume:73 Page:223-228
ISSN:0010-7824
Container-title:Contraception
language:en
Short-container-title:Contraception

Author:

Jick Susan S.,Kaye James A.,Russmann Stefan,Jick Hershel

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Reproductive Medicine

Reference18 articles.

1. http://www.fda.gov/cder/drug/infopage/orthoevra/default.htm.

2. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive;van den Heuvedl;Contraception,2005

3. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception;World Health Organization;Lancet,1995

4. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review;Gomes;Arch Intern Med,2004

5. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components;Jick;Lancet,1995

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024;MMWR. Recommendations and Reports;2024-08-08

2. An overview of contraception in women with obesity;Best Practice & Research Clinical Obstetrics & Gynaecology;2023-12

3. Reversible female contraceptives: historical, current, and future perspectives;Biology of Reproduction;2023-11-06

4. The new low-dose transdermal contraceptive system (Twirla®): results from preclinical and Phase III trials;Therapeutic Delivery;2021-07

5. Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions;PharmacoEconomics;2019-05-09